Healthcare Wrap: Dimerix Tumbles, TrivarX and LTR Pharma Race Ahead

• Dimerix sank 43.42% even after saying its kidney disease trial still has strong statistical power
• TrivarX jumped 31.25% and LTR Pharma rose 30.77% on clinical and leadership progress
• Fresh funding remained a major driver, with raises across 4DMedical, Paradigm, Botanix, Actinogen and others
• FDA and European approvals kept opening new sales markets for imaging, diagnostics and devices